(Q46856543)

25 December 2017

title

The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden (English)

1 reference

25 December 2017

0 references

0 references

1 reference

N Zethraeus

1

1 reference

25 December 2017

O Ström

2

1 reference

25 December 2017

F Borgström

3

1 reference

25 December 2017

J A Kanis

4

1 reference

25 December 2017

B Jönsson

5

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

25 December 2017

Osteoporosis International

published in

1 reference

25 December 2017

volume

19

1 reference

25 December 2017

issue

6

1 reference

25 December 2017

page(s)

819-827

1 reference

25 December 2017

Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Costs and quality of life associated with osteoporosis-related fractures in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Bone density and risk of hip fracture in men and women: cross sectional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

A meta-analysis of previous fracture and subsequent fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Willingness to pay for a quality-adjusted life year: in search of a standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Accounting for future costs in medical cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Long-term risk of osteoporotic fracture in Malmö.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Probability of stroke: a risk profile from the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-007-0511-0

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

21 January 2018

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

1 reference

12 December 2020

Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease

1 reference

12 December 2020

Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

10.1007/S00198-007-0511-0

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017